X4 Pharmaceuticals, Inc
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| X4 PHARMACEUTICALS, INC. | ||
| Date: March 25, 2025 | By: | /s/ Paula Ragan |
|---|---|---|
| Paula Ragan, Ph.D. | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Paula Ragan | President, Chief Executive Officer and Director | March 25, 2025 |
| Paula Ragan, Ph.D. | (Principal Executive Officer) | |
| /s/ Adam S. Mostafa | Chief Financial Officer and Treasurer | March 25, 2025 |
| Adam S. Mostafa | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Michael S. Wyzga | Chairman of the Board of Directors | March 25, 2025 |
| Michael S. Wyzga | ||
| /s/ William Aliski | Director | March 25, 2025 |
| William E. Aliski | ||
| /s/ Gary J. Bridger | Director | March 25, 2025 |
| Gary J. Bridger, Ph.D. | ||
| /s/ Francoise De Craecker | Director | March 25, 2025 |
| Francoise De Craecker | ||
| /s/ Alison Lawton | Director | March 25, 2025 |
| Alison F. Lawton | ||
| /s/ David McGirr | Director | March 25, 2025 |
| David McGirr | ||
| /s/ Murray W. Stewart | Director | March 25, 2025 |
| Murray W. Stewart, M.D. | ||
| /s/ Robert K. Woods | Director | March 25, 2025 |
| Robert K. Woods | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss | F-5 |
| Consolidated Statements of Stockholders’ Equity | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.